{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/ARWR/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-16T08:10:29.189Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8879,"canonical_name":"ARROWHEAD PHARMACEUTICALS, INC.","cik":"0000879407","uei":null,"lei":null,"duns":null,"ticker":"ARWR"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"clinical":5,"sec":10},"count":15,"timeline":[{"ts":"2026-10-06","kind":"clinical.trial","reporter":"Arrowhead Pharmaceuticals","title":"A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis","security_title":"PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07859813","excerpt":"[\"Metabolic Dysfunction-Associated Steatohepatitis\"]","importance":45},{"ts":"2026-09-15","kind":"clinical.trial","reporter":"Arrowhead Pharmaceuticals","title":"A First-In-Human Study of ARO-033 in Adult Participants","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07662096","excerpt":"[\"Age-related Macular Degeneration\"]","importance":30},{"ts":"2026-08-04","kind":"sec.filing","form_type":"10-Q","title":"10-Q — ARROWHEAD PHARMACEUTICALS, INC. — 2026-08-04","url_slug":"/sec/cik-0000879407/10-q/0000879407-26-000057","accession_number":"0000879407-26-000057","importance":45},{"ts":"2026-08-04","kind":"sec.filing","form_type":"8-K","title":"8-K — ARROWHEAD PHARMACEUTICALS, INC. — 2026-08-04","url_slug":"/sec/cik-0000879407/8-k/0000879407-26-000058","accession_number":"0000879407-26-000058","importance":35},{"ts":"2026-06-16","kind":"sec.filing","form_type":"8-K","title":"8-K — ARROWHEAD PHARMACEUTICALS, INC. — 2026-06-16","url_slug":"/sec/cik-0000879407/8-k/0000879407-26-000050","accession_number":"0000879407-26-000050","importance":35},{"ts":"2026-06-15","kind":"sec.insider.a","reporter":"Cohen Matthew Gregory","title":null,"shares":11882,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-19","kind":"sec.form144","reporter":"Daniel Apel","title":"Officer","shares":13095,"usd_value":934206,"security_title":"Common","approx_sale_date":"2026-04-22","accession_number":"0001628280-26-036528","importance":40.186841232},{"ts":"2026-05-19","kind":"sec.form144","reporter":"James Hamilton","title":"Officer","shares":10000,"usd_value":749998,"security_title":"Common","approx_sale_date":"2026-04-23","accession_number":"0001628280-26-036511","importance":40.14999952},{"ts":"2026-05-19","kind":"sec.form144","reporter":"Hongbo Lu","title":"Officer","shares":2970,"usd_value":228299,"security_title":"Common","approx_sale_date":"2026-05-12","accession_number":"0001628280-26-036522","importance":40.04565979},{"ts":"2026-05-19","kind":"sec.filing","form_type":"144/A","title":"144/A — Apel Daniel Joseph — 2026-05-19","url_slug":"/sec/cik-0002081169/144-a/0001628280-26-036528","accession_number":"0001628280-26-036528","importance":30},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"Arrowhead Pharmaceuticals","title":"Study of ARO-APOC3 in Adults With Dyslipidemia","security_title":"PHASE2","status":"COMPLETED","accession_number":"NCT05413135","excerpt":"[\"Dyslipidemias\"]","importance":45},{"ts":"2026-05-12","kind":"sec.form144","reporter":"Hongbo Lu","title":"Officer","shares":2970,"usd_value":228299,"security_title":"Common","approx_sale_date":"2026-05-12","accession_number":"0001628280-26-034153","importance":40.04565979},{"ts":"2026-05-12","kind":"sec.insider.s","reporter":"Lu Hongbo","title":null,"shares":2970,"price_per_share":76.88,"usd_value":228334,"security_title":"Common Stock","importance":35.2283336},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Arrowhead Pharmaceuticals","title":"Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease","security_title":"PHASE1,PHASE2","status":"COMPLETED","accession_number":"NCT05083364","excerpt":"[\"C3 Glomerulopathy\",\"IgA Nephropathy\"]","importance":45},{"ts":"2026-04-24","kind":"clinical.trial","reporter":"Arrowhead Pharmaceuticals","title":"A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT06700538","excerpt":"[\"Obesity\"]","importance":45}]}